Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to evaluate the effect of natalizumab exposure on pregnancy outcomes and disease activity during pregnancy

Next Previous
Trial Profile

A study to evaluate the effect of natalizumab exposure on pregnancy outcomes and disease activity during pregnancy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 07 Feb 2018 Results (n=83) assessing the risk of disease reactivation during pregnancy after natalizumab suspension compared with untreated patients and patients treated with injectable immunomodulatory agents published in the Neurology
    • 07 Feb 2018 Results (n=83) assessing fetal risk after pregnancy exposure to natalizumab in women with multiple sclerosis compared with untreated patients and patients treated with injectable immunomodulatory agents published in the Neurology
    • 21 Apr 2016 Safety results (n=59) of natalizumab exposed pregnancies in MS patients compared with the Italian dataset of interferon-beta (IFNB) exposed and non-exposed pregnancies were presented at the 68th Annual Meeting of the American Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top